Pantoprazol Vir Pharma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Vir Pharma, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Vir Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is indicated for several acid‑related gastrointestinal disorders.

Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of the esophageal lining. Erosive esophagitis: facilitates mucosal repair and alleviates pain. Peptic ulcer disease: supports ulcer healing and prevents recurrence. Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional during early treatment. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile infection: may cause severe colitis. - Low magnesium levels (hypomagnesemia): can lead to muscle cramps or arrhythmias. - Liver enzyme elevation: monitor hepatic function if symptoms arise.

Precautions should be observed when prescribing pantoprazole.

Assess renal function: dose adjustment may be needed in severe renal impairment. Monitor magnesium levels: prolonged therapy can cause hypomagnesemia. Avoid in known hypersensitivity to pantoprazole or other PPIs. Use caution in patients with liver disease: hepatic metabolism may be affected. Store at room temperature: keep in the original pack, protect from moisture and heat.

Pantoprazole may interact with several medications.

Major Interactions (Avoid): - Ketoconazole: reduced absorption due to decreased gastric acidity. - Atazanavir: decreased plasma concentrations, compromising efficacy. - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Warfarin: potential increase in INR, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, risk of toxicity. - Methotrexate: reduced clearance, possible accumulation. - Phenytoin: decreased levels, may reduce seizure control.